FDA Sets Date to Decide Zevalin's Fate in Treating NHL

by: cancercompass

Spectrum Pharmaceuticals Inc. says the United States Food and Drug Administration (FDA) has set September 7th as a decision date regarding experimental drug Zevalin's use in treating non-Hodgkin's lymphoma (NHL), reports Reuters.

The FDA recently accepted Spectrum's resubmission to review Zevalin, which typically means U.S. regulators would review the drug 60 days from the date of the submission's acceptance, says Reuters.

Zevalin is already approved to treat patients with relapsed or refractory, low-grade or follicular B-cell NHL.

Discuss your experiences with Zevalin or other medications used to treat non-Hodgkin's lymphoma at our Lymphoma Message Board.